All Articles

Patients who lost less than 20 pounds on GLP-1 medications and were subsequently prescribed phentermine experienced greater weight loss while on phentermine in the year following GLP-1 treatment than patients who lost at least 20 pounds on the GLP-1 medication. 

The use of DNA stool tests for colorectal cancer screening has increased nine-fold since 2018, rising from 3% of screenings in the first quarter of 2018 to 27% of screenings in the second quarter of 2023.

Non-diabetic patients prescribed liraglutide have an increased likelihood of experiencing delayed gastric emptying and ileus compared to those on a weight loss medication not classified as a glucagon-like peptide-1 receptor agonist (GLP-1). 

Diabetic patients prescribed four of the five glucagon-like peptide-1 receptor agonist (GLP-1) medications studied experienced increased likelihood of delayed gastric emptying (gastroparesis) compared to those not on a GLP-1 medication.

The incidence of cardiovascular disease (CVD) among adults under 40 has more than doubled since 2010, with rates increasing from 9.4 per 1,000 patients in 2010 to 22.0 per 1,000 patients by 2023.

Abdominal aortic aneurysm (AAA) screenings are being performed 73% more often in recent months compared to 2017 among patients eligible to be screened. 

Atrial fibrillation (AFib) patients with obstructive sleep apnea (OSA) have a higher rate of ischemic stroke compared to those without OSA.

Children aged 6 to 17 prescribed montelukast were slightly more likely to be diagnosed with suicidal ideation, depression, agitation, or aggression compared to those prescribed inhaled corticosteroids. However, that increase was not statistically significant. 

Primary lung cancer is more than twice as prevalent in women previously diagnosed with breast cancer compared to women who have not had breast cancer. 

Non-Hispanic Black patients are 32% more likely to have occult hypoxemia, which is an overestimation of a patient’s blood gas by a pulse oximeter that can lead to delayed recognition of low oxygen levels than non-Hispanic White patients.

After one year of treatment, patients on any dosage of tirzepatide or injectable semaglutide experienced greater median weight loss than those on any dosage of liraglutide, dulaglutide, or oral semaglutide.

Fentanyl toxicology testing in overdose ED encounters has more than tripled for most age groups since 2021. Patients aged 13 to 17 experienced the greatest increase in testing rates, going from 5% of encounters to 26% of encounters.

Children born to mothers who were obese or overweight before pregnancy and who maintain that BMI category after pregnancy have a significantly higher likelihood of being obese compared with children born to mothers who were not overweight both before and after pregnancy.

Despite a small decrease in late 2017, parenteral opioid administrations – those given by IV or injection – have risen from 23.3% of pain-related ED encounters in January 2014 to 26.4% of such encounters in December 2023.

Diabetic patients prescribed tirzepatide, semaglutide, dulaglutide, and exenatide are less likely to be diagnosed with depression after starting the medication compared to those not on a glucagon-like peptide-1 receptor agonist (GLP-1) medication.  

Testosterone replacement therapy (TRT) use is not correlated with an increased rate of testicular cancer.

In patients with a higher level of acuity in the emergency department, the presence of outside records is correlated with a 34-63% reduced risk of a code blue event depending on the patient’s age.

Children whose mothers were prescribed systemic antifungals in the year after birth are 16% more likely to develop a food allergy compared to those whose mothers were not prescribed an antifungal in the year after birth. 

More than half of patients are able to maintain weight loss achieved while on semaglutide or liraglutide even a year after discontinuing the medication.

Men with low testosterone on testosterone replacement therapy (TRT) have a 7.9% increased risk of cardiovascular disease (CVD) compared to those not on TRT.